Streetbeat News

Products Services

CLF

NEM

NUE

Nucor Corporation introduces a weekly Consumer Spot Price for hot-rolled coil, aiming for transparent pricing. Cleveland-Cliffs praises a new DOE standard benefiting its steel production, potentially increasing demand. Newmont concludes a $20M support fund for pandemic-affected communities. Analysts adjust price targets for Newmont and Ternium, reflecting market expectations.

Portfolio Pulse from Austin DeNoce

April 05, 2024 | 8:41 pm

ELTX

Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced it will present updated clinical and preclinical data at the AACR Annual Meeting. The data includes positive outcomes from the AMPLIFY-201 Phase 1 study of ELI-002, showing significant T cell responses in patients with mKRAS-driven cancers. Additionally, preclinical studies of ELI-007 and ELI-008 demonstrated substantial immune responses compared to conventional vaccines. ELTX plans to present initial ELI-002 7P clinical data in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:34 pm

HOWL

Werewolf Therapeutics, Inc. (HOWL) presented preclinical results at AACR 2024 showing anti-tumor effects of WTX-518 and WTX-712, engineered to stimulate the immune system for cancer treatment. WTX-518 led to complete tumor regressions in models, while WTX-712 showed potent antitumor activity with a unique immune activation mechanism. The company aims to develop these as immunotherapies for refractory or immunologically unresponsive tumors.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:32 pm

AMZN

GOOG

Decentralized Infrastructure Physical Networks (DePINs), leveraging blockchain technology, aim to disrupt tech monopolies by enabling decentralized access and management of internet, energy, and storage services. Highlighting the potential to democratize infrastructure, DePINs could offer solutions to underserved areas, incentivize participation through crypto tokens, and foster competition against centralized giants like Google and Amazon. Challenges include regulatory uncertainty and ensuring data privacy, but the initiative aligns with the broader Web3 vision of user control and data sovereignty.

Portfolio Pulse from Chris Were

April 05, 2024 | 8:29 pm

AAPL

AMZN

DIS

LLY

NKLA

XLE

Recent economic data and Federal Reserve officials' remarks have led investors to adjust expectations for interest rate cuts, as the U.S. economy shows resilience with job growth and manufacturing expansion. Energy stocks, particularly the Energy Select Sector SPDR Fund, benefited from rising oil prices. Apple is refocusing on home robotics, potentially entering a new market. Disney's board received strong shareholder support, affirming CEO Bob Iger's leadership. Eli Lilly faces supply challenges for its popular weight loss drugs on Amazon Pharmacy. Nikola Corp outperformed other EV stocks, including Tesla, Rivian, and Lucid, highlighting its recovery and focus on hydrogen fuel cell trucks.

Portfolio Pulse from Piero Cingari

April 05, 2024 | 8:23 pm

ABBV

Recent options activity for AbbVie (NYSE:ABBV) shows a bearish sentiment among investors, with 68% of trades being bearish. Significant trades have targeted a price range of $125.0 to $195.0. AbbVie, a pharmaceutical firm, is currently trading at $170.0, up 1.25%, with an RSI suggesting it may be approaching oversold. Analysts from Barclays and Guggenheim maintain positive ratings with target prices of $195 and $190, respectively.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:16 pm

AAPL

VGK

Apple has announced that it will allow music streaming apps in the European Economic Area to provide an external purchase link. This decision, reported by Reuters, marks a significant change in Apple's policy, potentially affecting its revenue from these apps.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:15 pm

23andMe Holding Co. (NASDAQ:ME) will present data on two clinical stage immuno-oncology programs at the AACR Annual Meeting 2024. The programs include 23ME-01473, targeting ULBP6, and 23ME-00610, targeting CD200R1. Both programs aim to enhance anti-tumor immunity, with '1473 focusing on restoring NK and T cell function and '00610 targeting the CD200R1 pathway for potential combination therapies. The presentations will showcase the discovery, preclinical data, and ongoing clinical trials for these antibodies.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:06 pm

OCGN

Ocugen, Inc. (NASDAQ:OCGN) shares rose after announcing approval to proceed with medium dose dosing in the Phase 1/2 study of OCU410. The Data and Safety Monitoring Board for the ArMaDa clinical trial approved this next step, highlighting the therapy's safety and potential as a one-time treatment for life. Ocugen also updated on progress in its gene therapy programs for blindness diseases. The company's stock is up 20%, trading at $1.81.

Portfolio Pulse from Erica Kollmann

April 05, 2024 | 7:56 pm

DKNG

DraftKings shares are trading higher, potentially due to the ongoing NCAA Tournament and overall market strength.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:47 pm